Judd, LL, Akiskal, HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003; 73(1–2): 123–131.
Angst, J, Cui, L, Swendsen, J, et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry. 2010; 167(10): 1194–1201. Epub ahead of print Aug 16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145248/. Accessed January 14, 2017.
Hoertel, N, Le Strat, Y, Angst, J, et al. Subthreshold bipolar disorder in a US national representative sample. prevalence, correlates, and perspectives for psychiatric nosography. J Affect Disord. 2013; 146(3): 338–347. Epub ahead of print Oct 3, 2012.
Angst, J, Gamma, A, Bowden, CL, et al. Evidence-based definitions of bipolar-I and bipolar-II disorders among 5,635 patients with major depressive episodes in the BRIDGE Study: validity and comorbidity. Eur Arch Psychiatry Clin Neurosci. 2013; 263(8): 663–673. Epub ahead of print Jan 31.
Benazzi, F, Akiskal, HS. Psychometric delineation of the most discriminant symptoms of depressive mixed states. Psychiatry Res. 2006; 141(1): 81–88. Epub ahead of print Nov 28, 2005.
Perlis, RH, Uher, R, Ostacher, M, et al. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry. 2011; 68(4): 351–360. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794668/. Accessed January 14, 2017.
Perugi, G, Angst, J, Azorin, JM, et al. Mixed features in patients with a major depressive episode. the BRIDGE–II–MIX Study. J Clin Psychiatry. 2015; 76(3): e351–e358.
McIntyre, RS, Soczynska, JK, Cha, DS, et al. The prevalence and illness characteristics of DSM–5-defined “mixed feature specifier” in adults with major depressive disorder and bipolar disorder: results from the International Mood Disorders Collaborative Project. J Affect Disord. 2014; 172: 259–264. Epub ahead of print Oct 12.
Smith, DJ, Forty, L, Russell, E, et al. Sub-threshold manic symptoms in recurrent major depressive disorder are a marker for poor outcome. Acta Psychiatr Scand. 2009; 119(4): 325–329. Epub ahead of print Dec 16, 2008.
Popovic, D, Vieta, E, Azorin, JM, et al. Suicide attempts in major depressive episode: evidence from the BRIDGE–II–Mix Study. Bipolar Disord. 2015; 17(7): 795–803. Epub ahead of print Sep 29.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
Ishibashi, T, Horisawa, T, Tokuda, K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010; 334(1): 171–181. Epub ahead of print Apr 19. http://jpet.aspetjournals.org/content/334/1/171.long. Accessed January 14, 2017.
Cates, LN, Roberts, AJ, Huitron-Resendiz, S, et al. Effects of lurasidone in behavioral models of depression: role of the 5-HT7 receptor subtype. Neuropharmacology. 2013; 70: 211–217. Epub ahead of print Feb 13.
Suppes, T, Silva, R, Cucchiaro, J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized. double-blind. placebo-controlled study. Am J Psychiatry. 2016; 173(4): 400–407. Epub ahead of print Nov 10, 2015.
Tohen, M, Frank, E, Bowden, CL, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorder. Bipolar Disord. 2009; 11(5): 453–473.
Goldberg, JF, Harrow, M. A 15-year prospective follow-up of bipolar affective disorders, comparison with unipolar depression. Bipolar Disord. 2011; 13(2): 155–163.
Loebel, A, Siu, C, Rajagopalan, K, Pikalov, A, Cucchiaro, J, Ketter, TA. Recovery in bipolar depression: Post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study. J Affect Disord. 2015; 186: 376–382. Epub ahead of print Aug 5. http://www.jad-journal.com/article/S0165-0327(15)30168-3/pdf. Accessed January 14, 2017.
Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382–389.
Guy, W. Early Clinical Drug Evaluation Assessment Manual for Psychopharmacology Publication ADM 76–338 Washington, DC: U.S. Department of Health, Education, and Welfare; 1976. P. 218–222. https://archive.org/details/ecdeuassessmentm1933guyw. Accessed January 14, 2017.
Sheehan, DV, Hamett-Sheehan, K, Raj, BA. The measurement of disability. Int Clin Psychopharmacol. 1996; 11(Suppl. 3): S89–S95.
Judd, LL, Schettler, PJ, Rush, J, et al. A new empirical definition of major depressive episode recovery and its positive impact on future course of illness. J Clin Psychiatry. 2015; 77(8): 1065–1073.
Sachs, GS, Nierenberg, AA, Calabrese, JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007; 356(17): 1711–1722. Epub ahead of print Mar 28. http://www.nejm.org/doi/pdf/10.1056/NEJMoa064135. Accessed January 14, 2017.
Tohen, M, McDonnell, DP, Case, M, et al. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry. 2012; 207(5): 376–382. Epub ahead of print Aug 23. http://bjp.rcpsych.org/content/201/5/376.long. Accessed January 14, 2017.
Sheehan, KH, Sheehan, DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale.
Int. Clin. Psychopharmacol
. 2008; 23(2): 70–83.
Sheehan, DV, Myers, AL, Prakash, A, et al. The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Curr Med Res Opin. 2008; 24(9): 2457–2466. Epub ahead of print Jul 24.
Mancini, M, Sheehan, DV, Demyttenaere, K, et al. Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan Disability Scale, pooled analysis of data from six randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol. 2012; 27(6): 298–309.
Bijl, RV, Ravelli, A. Current and residual functional disability associated with psychopathology: findings from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Psychol Med. 2000; 30(3): 657–668.
Simon, GE, Revicki, D, Heiligenstein, J, et al. Recovery from depression, work productivity and health care costs among primary care patients. Gen Hosp Psychiatry. 2000; 22(3): 153–162.
McIntyre, RS, Lee, Y, Mansur, RB. Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr. 2015; 20(Suppl. 1): 17–31.
van der Voort, TY, Seldenrijk, A, van Meijel, B, et al. Functional versus syndromal recovery in patients with major depressive disorder and bipolar disorder. J Clin Psychiatry. 2015; 76(6): e809–e814.
Conradi, HJ, Ormel, J, de Jonge, P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011; 41(6): 1165–1174.
Rajagopalan, K, Bacci, ED, Wyrwich, KW, Pikalov, A, Loebel, A. The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial. Int J Bipolar Disord. 2016; 4(1): Epub ahead of print Mar 16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792823/. Accessed January 14, 2017.
Vieta, E, Valentí, M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013; 27(7): 515–529.